Clinical Trials Logo
  1. Home
  2. Non-Metastatic Prostate Cancer
  3. NCT00239291

Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

Non-Metastatic Prostate Cancer Clinical Trial

Official title:
A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer

Clinical Trial Summary

To estimate the safety and tolerability of 250 mg ZD1839 given concurrently with 3D-CRT in patients with non-metastatic prostate cancer

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00239291
Study type Interventional
Source AstraZeneca
Contact
Status Completed
Phase Phase 1/Phase 2
Start date January 2003
Completion date May 2006
View Details
See also
  Status Clinical Trial Phase
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT00673205 - (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer Phase 3
Completed NCT00672282 - Casodex vs Placebo in Non-Metastatic Early Prostate Cancer Phase 3
Recruiting NCT06202248 - A Study to Assess Alpha DaRT224 for the Treatment of Men With Non-metastatic Locally Recurrent Prostate Cancer N/A
Recruiting NCT01317043 - A Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy Phase 2
Completed NCT06204302 - An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
Recruiting NCT04049747 - Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer N/A
Active, not recruiting NCT05617885 - Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer Phase 1/Phase 2
Completed NCT00657904 - Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer Phase 3